Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    HomeNewsSunpharmaadvancedresearchcompany

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Buy SPARC, JSW Steel, SRF: Ashwani Gujral

      Buy SPARC, JSW Steel, SRF: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one can buy Sun Pharmaceutical Advanced Research Company, JSW Steel and SRF.

    • Buy DHFL, M&M Fin, Reliance Infra, SPARC: Ashwani Gujral

      Buy DHFL, M&M Fin, Reliance Infra, SPARC: Ashwani Gujral

      According to Ashwani Gujral of ashwanigujral.com, one can buy DHFL, Mahindra and Mahindra Financial Services, Reliance Infrastructure and Sun Pharma Advanced Research Company.

    • Buy SPARC, Magma Fincorp, Balrampur Chini, JK Lakshmi: Gujral

      Buy SPARC, Magma Fincorp, Balrampur Chini, JK Lakshmi: Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying Sun Pharma Advance Research Company, Magma Fincorp, Balrampur Chini and JK Lakshmi Cement.

    • Pick ICICI Bank, SPARC, GIC Housing: Vijay Chopra

      Pick ICICI Bank, SPARC, GIC Housing: Vijay Chopra

      Vijay Chopra of enochventures.com is of the view that one may pick ICICI Bank and Sun Pharma Advanced Research Company.

    • Buy Sun Pharma Advanced, Mercator, M&M Financial: Ashwani Gujral

      Buy Sun Pharma Advanced, Mercator, M&M Financial: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one can buy Sun Pharma Advanced Research Company, Mercator and Mahindra & Mahindra Financial Services.

    • Buy Dena Bank, SREI Infra, Biocon, Sun Pharma Adv: Gujral

      Buy Dena Bank, SREI Infra, Biocon, Sun Pharma Adv: Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying Dena Bank, SREI Infra, Kesoram Industries, Biocon and Sun Pharma Advanced Research Company.

    • Buy Tata Global Beverage, UPL may test Rs 598: Rajat Bose

      Buy Tata Global Beverage, UPL may test Rs 598: Rajat Bose

      Rajat Bose of rajatkbose.com recommends buying Tata Global Beverage and feels that UPL may test Rs 598.

    • Buy SPARC, Idea Cellular; sell UPL: Ashwani Gujral

      Buy SPARC, Idea Cellular; sell UPL: Ashwani Gujral

      Ashwani Gujral, of ashwanigujral.com recommends buying Sun Pharma Advanced Research Company and Idea Cellular and advises selling UPL.

    • Hold SPARC, says Sharmila Joshi

      Hold SPARC, says Sharmila Joshi

      Sharmila Joshi of sharmilajoshi.com is of the view that one may hold Sun Pharma Advanced Research Company.

    • Hold Sun Pharma Advanced, says Sandeep Wagle

      Hold Sun Pharma Advanced, says Sandeep Wagle

      Sandeep Wagle of powermywealth.com is of the view that one may hold Sun Pharma Advanced Research Company with long term perspective.

    • Buy L&T, Bank of Baroda, Ashok Leyland: Rajat Bose

      Buy L&T, Bank of Baroda, Ashok Leyland: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that one may buy YES Bank, L&T, Bank of Baroda and Ashok Leyland.

    • Bull's Eye: Buy HDIL, Wockhardt, SPARC, Voltas; sell ITC

      Bull's Eye: Buy HDIL, Wockhardt, SPARC, Voltas; sell ITC

      Jay Thakkar of Sharekhan suggests selling ITC with a target of Rs 281.70.

    • Sun Pharmaceutical Advanced may hit Rs 354: Rajat Bose

      Sun Pharmaceutical Advanced may hit Rs 354: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that Sun Pharmaceutical Advanced Research Company may hit Rs 354.

    • Bull's Eye: Buy SPARC, BEL, NCC, Sun Pharma, LIC Housing

      Bull's Eye: Buy SPARC, BEL, NCC, Sun Pharma, LIC Housing

      Dharmesh Kant of India Nivesh Securities is of the view that one may buy NCC with a target of Rs 90.

    • Bull's Eye: Buy Ashok Leyland, UPL, NIIT, SPARC, Aurobindo

      Bull's Eye: Buy Ashok Leyland, UPL, NIIT, SPARC, Aurobindo

      Shahina Mukadam, Independent Market Expert advises buying Ashok Leyland with a target of Rs 94.

    • Bull's Eye: Buy BHEL, SPARC, IGL, Suzlon, Dish TV, Nilkamal

      Bull's Eye: Buy BHEL, SPARC, IGL, Suzlon, Dish TV, Nilkamal

      Kiran Jadhav of Precision Investment Services is of the view that one may buy Suzlon Energy with a target of Rs 25.50.

    • Pick Sun Pharma Advanced on dips, says Kunal Bothra

      Pick Sun Pharma Advanced on dips, says Kunal Bothra

      Kunal Bothra of LKP Securities advises buying Sun Pharma Advanced Research Company on dips.

    • Bullish Sun Pharma; see over 20% rise by Dec '16: JP Morgan

      Bullish Sun Pharma; see over 20% rise by Dec '16: JP Morgan

      While JP Morgan warns of volatile quarterly results owing to one-time charges, it says the potential upside from the Ranbaxy deal in the medium-term (synergies from FY17 onwards) does strengthen the case for buying the stock at current levels.

    • Top buzzing midcap stocks to trade on September 8

      Top buzzing midcap stocks to trade on September 8

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - Infosys, NTPC, Indiabulls Housing Finance, Ceat, Sun Pharma Advanced Research, ITC.

    • Buy Aurobindo Pharma on declines: Mayuresh Joshi

      Buy Aurobindo Pharma on declines: Mayuresh Joshi

      According to Mayuresh Joshi of Angel Broking, one may buy Aurobindo Pharma on declines for a target of Rs 872.

    • Buy SPARC, Alembic, TV Today; sell Oil India: Mukadam

      Buy SPARC, Alembic, TV Today; sell Oil India: Mukadam

      Shahina Mukadam, Market Expert recommends buying TV Today Network with a target of Rs 202 and advises selling Oil India with a target of Rs 410.

    • Expect levels of Rs 438-443 in SPARC, says Rajat Bose

      Expect levels of Rs 438-443 in SPARC, says Rajat Bose

      According to Rajat Bose of rajatkbose.com, Sun Pharma Advanced Research Company may hit Rs 438-443 and may even get to Rs 449.

    • Bull's Eye: Buy Voltas, Rel Comm, OBC, sell Oil India

      Bull's Eye: Buy Voltas, Rel Comm, OBC, sell Oil India

      According to Shahina Mukadam, Market Expert, one may buy Sun Pharma Advanced Research Company (SPARC) with a target of Rs 440.

    • Bull's Eye: Buy HPCL, UPL, Dish TV, Apollo Tyres, sell NTPC

      Bull's Eye: Buy HPCL, UPL, Dish TV, Apollo Tyres, sell NTPC

      According to Rakesh Bansal of RK Global, one may buy Anant Raj with a target of Rs 44.50 and Dish TV with a target of Rs 114.

    • Buy Sun Pharma Advanced Research on dips: Prakash Diwan

      Buy Sun Pharma Advanced Research on dips: Prakash Diwan

      Prakash Diwan of Altamount Capital is of the view that one can buy Sun Pharma Advanced Research Company on dips.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347